TORONTO, May 7 /CNW/ - Patheon Inc. (TSX: PTI), a global provider of drug
development and manufacturing services to the international pharmaceutical
industry, announced that it has filed voting results in respect of its 2009
annual meeting of its shareholders. The voting results originally filed on
SEDAR on May 1, 2009 overstated the number of votes cast in favour of Messrs.
Bussandri, Currie, Green, Watchorn, Voorheis and Graydon by 4,514,200. The
corrected voting results did not affect the determination of which individuals
were elected to the board of directors of the Company at the meeting.
Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of
contract development and manufacturing services to the global pharmaceutical
industry. Patheon prides itself in providing the highest quality products and
services to more than 300 of the world's leading pharmaceutical and
biotechnology companies. Patheon's services range from preclinical development
through commercial manufacturing of a full array of dosage forms including
parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative
technologies including single-use disposables, Liquid-Filled Hard Capsules and
a variety of modified release technologies.
Patheon's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization. Patheon
can take customers direct to clinic with global clinical packaging and
distribution services and Patheon's Quick to Clinic(TM) programs can
accelerate early phase development project to clinical trials while minimizing
the consumption of valuable API. Patheon's integrated network strives to
ensure that customer products can be launched with confidence globally.
For further information:
For further information: Mr. Wes Wheeler, President & Chief Executive
Officer, Tel: (919) 226-3200, Email: firstname.lastname@example.org; Ms. Doaa A.
Fathallah, Senior Vice President, General Counsel - Europe, Global PDS &
Corporate Secretary, Tel: +41 41 766 2580, Email: email@example.com